Brief: Pardes Biosciences Says FDA Granted Fast Track Designation For PBI-0451
09/06/2022 11:10
June 9 (Reuters) - Pardes Biosciences Inc PRDS.O :
* PARDES BIOSCIENCES INC - ON JUNE 6, FDA GRANTED FAST TRACK
DESIGNATION FOR PBI-0451
* PARDES BIOSCIENCES - SEES ENROLLING GLOBAL,
PLACEBO-CONTROLLED
PHASE 2 CLINICAL TRIAL IN VACCINATED/UNVACCINATED PARTICIPANTS
WITH MILD-TO-MODERATE COVID-19 LATER THIS YEAR
* PARDES BIOSCIENCES - ANTICIPATES GENERATING DATA FROM
PHASE 3
REGISTRATIONAL TRIALS IN 2023
Source text for Eikon: [https://bit.ly/3aS4irp]
Further company coverage: PRDS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pardes Biosciences
See all newsBrief: Pardes Biosciences Inc - Total Cash Amount That Medipacific Sub, Inc. Will Pay Pursuant To Terms Of Offer And Merger Agreement Is $2.13 Per Share
U.S. STOCKS ON THE MOVE-Argenx, ViewRay, Ford
Pardes Biosciences up on buyout deal with MediPacific
U.S. STOCKS ON THE MOVE-Activision Blizzard, Tesla, Paramount Global
Pardes Biosciences gains on buyout deal with MediPacific